Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
XOresearch has developed an innovative Artificial Intelligence solution for the automatic annotation and analysis of electrocardiograms. This comprehensive tool serves three primary functions: it enhances clinical diagnosis productivity, facilitates remote patient monitoring, and offers readily available software for digital health devices and applications. CardioAI® stands out as a sophisticated productivity enhancer that speeds up the analysis of electrocardiograms, proving particularly beneficial in scenarios requiring continuous or extended cardiac monitoring. Its deployment significantly improves health surveillance capabilities, especially in remote, challenging, or hazardous environments. The system's ability to deliver accurate near real-time processing enables unparalleled medical assistance. Furthermore, CardioAI® can seamlessly integrate into electronic health record (EHR) systems or operate as part of mobile health devices. This commercially available software is versatile enough to be customized to meet various business needs. Additionally, CardioAI® guarantees precise and comprehensive annotation of stress, rest, and Holter electrocardiograms, adhering strictly to the HL7® aECG standard, which ensures consistency and reliability in data interpretation. Its adaptability and efficiency make it an invaluable asset in modern healthcare practices.
Description
Introducing a versatile API designed to seamlessly integrate with your diabetes management system, offering tailored therapeutic education and enhanced insights into blood glucose level fluctuations. This solution enables real-time risk predictions, fostering greater personalization and improved system regulation, while adeptly managing complex living scenarios characterized by rapid glucose variations. With advancements in telemedicine and retrospective analysis, patients receive robust decision-support tools. Currently, Hillo is developing the next iterations of its AI technology, which includes a therapeutic recommendation system aimed at preventing hypoglycemia and hyperglycemia, anticipated to achieve CE mark class IIB by 2020. Additionally, a new generation of the artificial pancreas is projected for release in 2021, addressing key limitations of existing systems through ultra-personalization driven by machine learning. This innovative approach marks the introduction of the first self-learning artificial intelligence capable of predicting blood glucose levels, aiming to secure a CE mark as a medical device, thereby transforming diabetes management for users. In essence, Hillo's advancements could significantly enhance the quality of life for individuals managing diabetes.
API Access
Has API
API Access
Has API
Integrations
Adobe Acrobat
Pricing Details
No price information available.
Free Trial
Free Version
Pricing Details
No price information available.
Free Trial
Free Version
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Vendor Details
Company Name
XOresearch
Founded
2015
Country
Latvia
Website
cardio.ai/
Vendor Details
Company Name
Hillo
Country
France
Website
www.hillo.ai/
Product Features
Remote Patient Monitoring
Dashboard
Data Import/Export
HIPAA Compliant
Mobile Payments
Monitoring Device Integration
Patient Engagement
Patient Portal
Patient Records Management
Patient Surveys
Reminders
Virtual Visits
Speech Recognition
Audio Capture
Automatic Form Fill
Automatic Transcription
Call Analysis
Concatenated Speech
Continuous Speech
Customizable Macros
Multi-Languages
Specialty Vocabularies
Speech-to-Text Analysis
Variable Frequency
Voice Recognition